Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
May 2019
Historique:
received: 10 10 2018
accepted: 18 01 2019
pubmed: 10 4 2019
medline: 18 12 2019
entrez: 10 4 2019
Statut: ppublish

Résumé

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health-related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology-specific, cancer-specific, SC-specific, facial SC-specific, NMSC-specific, basal cell carcinoma-specific and melanoma-specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF-36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer-specific EORTC QLQ-C30, especially in late stages of disease, and the melanoma-specific FACT-M and SC-specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology-specific HRQoL instruments can be used to assess the impact of skin-related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC.

Identifiants

pubmed: 30963614
doi: 10.1111/jdv.15487
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

816-827

Informations de copyright

© 2019 European Academy of Dermatology and Venereology.

Auteurs

P V Chernyshov (PV)

Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine.

A Lallas (A)

First Department of Dermatology, Aristotle University, Thessaloniki, Greece.

L Tomas-Aragones (L)

Department of Psychology, University of Zaragoza, Zaragoza, Spain.

M Arenbergerova (M)

Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

M Samimi (M)

Dermatology Department, University of Tours, Tours, France.

L Manolache (L)

Dermatology, Dali Medical, Bucharest, Romania.

A Svensson (A)

Department of Dermatology and Venereology, Skane University Hospital, Malmö, Sweden.

S E Marron (SE)

Department of Dermatology, Royo Villanova Hospital, Aragon Psychodermatology Research Group (GAI+PD), Zaragoza, Spain.

F Sampogna (F)

Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS FLMM, Rome, Italy.

S Spillekom-vanKoulil (S)

Radboud Institute for Health Sciences, Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands.

A Bewley (A)

Whipps Cross University Hospital, London, UK.
The Royal London Hospital, London, UK.

A M Forsea (AM)

Department of Oncologic Dermatology and Allergology, Elias University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

G B Jemec (GB)

Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark.

J C Szepietowski (JC)

Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.

M Augustin (M)

Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

A Y Finlay (AY)

Department of Dermatology and Wound Healing, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH